Monday 16 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.44
0.15
−4.18%
Follow KYNB
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 183 | 131 | 213 | 257 | 176 | 235 | 141 | 47 | 30 | 6 | 5 | (31.1%) | 6 | 7 | 7 | +3.8% | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 99.55 | 94.97 | 94.53 | 85.59 | 91.53 | 47.47 | 91.37 | 6.28 | (8.6) pt | ||||||
| EBT | (58) | (121) | (86) | (77) | (189) | (291) | (295) | (323) | (153) | (58) | (31) | 0.0% | ||||||
| EBT margin, % | (31.74) | (92.03) | (40.44) | (29.87) | (107.04) | (123.53) | (209.52) | (690.60) | (517.76) | (905.19) | (669.57) | (873.4) pt | ||||||
| Net income | (58) | (121) | (86) | (77) | (189) | (290) | (294) | (284) | (48) | 183 | 183 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 72.99 | 44.87 | 63.33 | 74.04 | 49.06 | 63.70 | 37.60 | 12.03 | 7.40 | 1.59 | 1.14 | (34.6%) | |||||
| Earnings | (24.50) | (43.25) | (25.75) | (22.25) | (52.75) | (78.50) | (78.50) | (73.00) | (12.00) | 45.37 | 45.30 | n/m | ||||||
| Cash flow | 2.83 | (22.78) | (22.65) | (22.71) | 22.70 | (22.26) | (38.99) | (80.94) | (34.48) | (1.18) | (9.40) | n/m | ||||||
| Capex | (0.50) | (2.91) | (2.33) | (1.66) | (1.11) | (8.17) | (10.35) | (0.65) | 0.19 | (0.01) | 0.00 | (35.7%) | ||||||
| Free cash flow | 2.33 | (25.69) | (24.98) | (24.37) | 21.59 | (30.43) | (49.33) | (81.59) | (34.29) | (1.19) | (9.40) | n/m | ||||||
| Book value | 69.77 | 187.61 | 157.17 | 154.50 | 122.82 | 62.02 | (0.40) | (47.19) | (51.25) | (4.21) | (7.32) | n/m | ||||||
| Shares, m | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | +5.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.08 | 0.0 | |||||
| P/S | 7.30 | 28.25 | 18.27 | 14.48 | 18.90 | 5.53 | 10.61 | 0.55 | 1.79 | 5.51 | 3.10 | 11.1 | ||||||
| P/B | 7.63 | 6.76 | 7.36 | 6.94 | 7.55 | 5.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.2 | ||||||
| EV/Sales | 6.44 | 23.38 | 15.81 | 12.60 | 15.23 | 4.31 | 8.37 | (0.26) | 2.95 | 14.55 | 15.20 | 10.3 | ||||||
| EV/FCF | 201.61 | (40.83) | (40.08) | (38.28) | 34.60 | (9.02) | (6.38) | 0.12 | (0.64) | (19.47) | (1.84) | 8.2 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 7 | (67) | (76) | (79) | 82 | (82) | (146) | (315) | (138) | (5) | (38) | n/m | |||||
| Capex | (1) | (8) | (8) | (6) | (4) | (30) | (39) | (3) | 1 | 0 | 0 | (32.2%) | ||||||
| Free cash flow | 6 | (75) | (84) | (84) | 78 | (112) | (185) | (318) | (137) | (5) | (38) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 201 | 663 | 601 | 600 | 592 | 249 | 219 | 114 | 63 | 70 | 61 | (11.1%) | |||||
| Net debt | (156) | (638) | (513) | (496) | (661) | (299) | (325) | (132) | 23 | (89) | (91) | (6.0%) | ||||||
| Shareholders’ equity | 175 | 548 | 528 | 535 | 441 | 229 | (1) | (184) | (205) | (17) | (30) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (12.35) | (17.67) | (9.71) | (8.86) | (22.48) | (36.24) | (42.44) | (55.00) | (14.91) | 109.81 | 131.26 | +122.2 pt | |||||
| ROIC | (162.20) | 0.00 | (360.67) | (142.19) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +162.2 pt | ||||||
| ROE | (31.22) | (33.44) | (16.06) | (14.47) | (38.76) | (86.50) | (258.01) | 307.01 | 24.48 | (165.18) | (157.83) | (134.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 364 | 423 | 461 | 531 | 599 | 566 | 592 | 486 | 225 | 34 | — | (23.2%) | |||||
| Revenue/emp, $m | 0.50 | 0.31 | 0.46 | 0.48 | 0.29 | 0.42 | 0.24 | 0.10 | 0.13 | 0.19 | — | (10.3%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026
Kyntra Bio Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MRKR MARKER THERAPEUTICS, INC. | $15.0M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| JSPR Jasper Therapeutics, Inc. | $14.8M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $14.6M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| KYNB Kyntra Bio Inc | $14.5M | 0.1× | — (loss-making) | −209.35% (below 0%: shrinking) | n/m | −131.50% (below 0%: shrinking) | 100.14% | 1,192.27% | |
| ALLR Allarity Therapeutics, Inc. | $14.5M | — (loss-making) | — (loss-making) | — | n/m | +15.63% (above 0%: growing) | 100.00% | (110,140.00%) | Compare |
| NCEL NewcelX Ltd. | $14.5M | — (loss-making) | — | — | — | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| QNTM Quantum Biopharma Ltd. | $14.4M | — (loss-making) | — (loss-making) | — | n/m | +5.88% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MCRB Seres Therapeutics, Inc. | $14.4M | — (loss-making) | — (loss-making) | +68.95% (above 0%: growing) | n/m | −574.29% (below 0%: shrinking) | 100.00% | (2,723.78%) | Compare |
| Median of peers | $14.5M | — | — | −51.00% | — | −74.10% | 74.39% | (221.45%) |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
4.15%
Armistice Capital, LLC
9.35%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Kyntra Bio Inc (KYNB) Latest News
- Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ... transcript
- Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ... GuruFocus.com
- Kyntra Bio (KYNB) Q1 2026 Earnings Transcript The Motley Fool transcript
- Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript The Motley Fool transcript
- Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 GlobeNewswire
- What sets FGEN apart? Diversification, ESG and growth opportunities - FGEN P5 Proactive
- Where FGEN sees growth beyond wind and solar - FGEN P4
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum GlobeNewswire
- Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration GlobeNewswire
20 more headlines
- Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors GlobeNewswire
- Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
- Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript The Motley Fool transcript
- Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
- Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
- Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
- Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates Zacks
- Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
- Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know Zacks
- Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ... GuruFocus.com
- Kyntra Bio: Q4 Earnings Snapshot Associated Press Finance
- Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
- Inside FGEN’s inflation-linked income and dividend strategy - FGEN P3 Proactive
- FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit GlobeNewswire
- FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... GuruFocus.com
- FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates ZacksAssociated Press FinanceZacksZacksZacksZacksZacksZacks
- FibroGen: Q3 Earnings Snapshot
- FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswireGuruFocus.comMotley FoolGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com
- FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer GlobeNewswire
- Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Forecasts Report 2025-2030 | Boehringer Ingelheim and FibroGen Lead by Driving Innovations in Pharmacological and Diagnostic Advancements